Abstract

DNMT3A mutations in patients with polycythemia vera were heterogeneous and not enriched in interferon alfa–treated patients. DNMT3A mutations had no detectable impact on the hematologic response, molecular response, or survival outcomes.

Subjects:
Clinical Trials and Observations, Myeloid Neoplasia
1.
Usart
M
,
Stetka
J
,
Luque Paz
D
, et al.
Loss of Dnmt3a increases self-renewal and resistance to pegIFN-α in JAK2-V617F–positive myeloproliferative neoplasms
.
Blood
.
2024
;
143
(
24
):
2490
-
2503
.
Google Scholar
Crossref
Search ADS
PubMed
 
2.
Knudsen
TA
,
Skov
V
,
Stevenson
K
, et al.
Genomic profiling of a randomized trial of interferon-α vs hydroxyurea in MPN reveals mutation-specific responses
.
Blood Adv
.
2022
;
6
(
7
):
2107
-
2119
.
Google Scholar
Crossref
Search ADS
PubMed
 
3.
Abu-Zeinah
G
,
Krichevsky
S
,
Cruz
T
, et al.
Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival
.
Leukemia
.
2021
;
35
(
9
):
2592
-
2601
.
Google Scholar
Crossref
Search ADS
PubMed
 
4.
Gisslinger
H
,
Klade
C
,
Georgiev
P
, et al.
Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment
.
Leukemia
.
2023
;
37
(
10
):
2129
-
2132
.
Google Scholar
Crossref
Search ADS
PubMed
 
5.
Silver
RT
.
Recombinant interferon-alpha for treatment of polycythaemia vera
.
Lancet
.
1988
;
2
(
8607
):
403
.
Google Scholar
Crossref
Search ADS
PubMed
 
6.
Barosi
G
,
Mesa
R
,
Finazzi
G
, et al.
Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project
.
Blood
.
2013
;
121
(
23
):
4778
-
4781
.
Google Scholar
Crossref
Search ADS
PubMed
 
7.
Cerami
E
,
Gao
J
,
Dogrusoz
U
, et al.
The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data
.
Cancer Discov
.
2012
;
2
(
5
):
401
-
404
.
Google Scholar
Crossref
Search ADS
PubMed
 
8.
Tefferi
A
,
Guglielmelli
P
,
Lasho
TL
, et al.
Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera
.
Br J Haematol
.
2020
;
189
(
2
):
291
-
302
.
Google Scholar
Crossref
Search ADS
PubMed
 
9.
Gisslinger
H
,
Klade
C
,
Georgiev
P
, et al.
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study
.
Lancet Haematol
.
2020
;
7
(
3
):
e196
-
e208
.
Google Scholar
Crossref
Search ADS
PubMed
 
10.
Barosi
G
,
Birgegard
G
,
Finazzi
G
, et al.
Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference
.
Blood
.
2009
;
113
(
20
):
4829
-
4833
.
Google Scholar
Crossref
Search ADS
PubMed
 
11.
Williams
N
,
Lee
J
,
Mitchell
E
, et al.
Life histories of myeloproliferative neoplasms inferred from phylogenies
.
Nature
.
2022
;
602
(
7895
):
162
-
168
.
Google Scholar
Crossref
Search ADS
PubMed
 
12.
Constantinescu
SN
,
Vainchenker
W
.
DNMT3A gates IFN-induced MPN HSC exhaustion
.
Blood
.
2024
;
143
(
24
):
2445
-
2446
.
Google Scholar
Crossref
Search ADS
PubMed
 
13.
Xavier Raj
I
,
Koh
WK
,
Harrison
J
, et al.
Dnmt3a controls hematopoietic stem cells via DNA methylation-independent regulation of telomeres [abstract]
.
Blood
.
2024
;
144
(
suppl 1
):
25
.
Google Scholar
 
© 2025 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
2025
You do not currently have access to this content.
Sign in via your Institution